Molecular Cloning & Expression of Platelet Adp Receptor

We will develop a novel therapeutic for the prevention of chronic thrombotic conditions (e.g., recumyocardial infarction) in patients with previous history of heart disease. ADP has been implicated aactivator in hemostasis and arterial thrombosis. The platelet ADP receptor is thought to be expressemegakaryocytes and therefore seems to be an optimal target for drugs modulating platelet activation.high-throughput screening assays for ADP receptor antagonists has been impaired by the unavailabilitcDNA and cell lines overexpressing the receptor. The specific aim of this Phase I study is to isolatusing Xenopus laevis oocyte expression technology and PCR cloning of novel platelet members of the Greceptor superfamily related to known P/2 purinoceptors. Successful completion of this proposal willapplication where we will utilize the receptor cDNA to generate cell lines overexpressing the receptthroughput screening assays to detect novel leads derived from a variety of natural product and syntlibraries. The resulting therapeutics should be effective in the treatment and prevention of stroke,diseases and thrombotic complications following angioplasty and other invasive procedures.